Safety of bevacizumab (BV) plus docetaxel (D) in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) who developed brain metastases during the AVADO phase III study

被引：0
|
作者：
Dirix, L. Y.
Romieu, G.
Provencher, L.
Grimes, D.
de Souzo, Viana L.
Paterson, A.
Mauriac, L.
Kirsch, A.
Pernas, S.
Miles, D. W.
机构：
[1] Oncol Ctr AZ St Augustinus Oncol, Antwerp, Belgium
[2] CRLCC Val Aurelle, Montpellier, France
[3] Hop St Sacrement, Quebec City, PQ, Canada
[4] Brisbane Haematol Oncol Clin, Auchenflower, Australia
[5] Hosp Canc Barretos, Barretos, Brazil
[6] Tom Baker Canc Clin, Calgary, AB, Canada
[7] Inst Bergonie, Bordeaux, France
[8] Onkol Schwerpunki Oskar Helene Heim, Berlin, Germany
[9] Inst Catala Oncol, Barcelona, Spain
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：285S / 285S
页数：1
相关论文
共 50 条
  • [41] Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
    Lima, C. S. Rocha
    Baranda, J. C.
    Wallmark, J.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [42] PROGRESSION-FREE SURVIVAL (PFS) IMPROVEMENTS IN PATIENT SUBGROUPS IN AVADO, A LARGE, RANDOMISED, DOUBLE-BLIND PHASE III STUDY OF BEVACIZUMAB (BV) IN COMBINATION WITH TAXANE CHEMOTHERAPY IN FIRST-LINE METASTATIC BREAST CANCER (MBC)
    Schneeweiss, A.
    Puglisi, F.
    Provencher, L.
    Delozier, T.
    Sohn, J. H.
    Draganescu, M.
    Verma, S.
    Delaloge, S.
    Kim, S. B.
    Miles, D. W.
    ANNALS OF ONCOLOGY, 2008, 19 : 44 - 44
  • [43] Phase III study of gemcitabine plus docetaxel versus capecitabine plus docetaxel for anthracycline-pretreated metastatic breast cancer patients: survival results
    Chan, S.
    Romieu, G.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Llombart, A.
    du Bois, A.
    Carrasco, E.
    Thareau, Vaury A.
    Fumoleau, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S68 - S68
  • [44] SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)
    Lang, I.
    Inbar, M.
    Greil, R.
    Kahan, Z.
    Beslija, S.
    Steger, G. G.
    Stemmer, S. M.
    Zvribule, Z.
    Kaufman, B.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 98
  • [45] Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study
    Masuda, Norikazu
    Iwata, Hiroji
    Aogi, Kenjiro
    Xu, Yihuan
    Ibrahim, Ayman
    Gao, Ling
    Dalal, Rita
    Yoshikawa, Reigetsu
    Sasaki, Yasutsuna
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (12) : 1088 - 1094
  • [46] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.
    Beslija, S.
    Brodowicz, T.
    Greil, R.
    Inbar, M. J.
    Kahan, Z.
    Kaufman, B.
    Lang, I.
    Steger, G. G.
    Stemmer, S. M.
    Zielinski, C.
    Zvirbule, Z.
    CANCER RESEARCH, 2011, 71
  • [47] A phase I study of docetaxel (D) in combination with high dose cyclophosphamide (C) as first line chemotherapy in patients (pts) with metastatic breast carcinoma (MBC)
    Cuvier, C
    Romieux, G
    Culine, S
    Boccara, C
    Espié, M
    Cottu, P
    Marty, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S329 - S330
  • [48] A phase II study of docetaxel (T) and capecitabine W combination chemotherapy as first-line chemotherapy for patients (pts) with metastatic breast cancer (MBC).
    Lim, HS
    Lee, HG
    Chun, JH
    Lee, JJ
    Lee, JS
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 100S - 100S
  • [49] A phase Ib study of the safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) plus cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J.
    Lieu, C.
    Raghav, K. P. S.
    Argiles, G.
    Cubillo, A.
    Qu, X.
    Yan, Y.
    Merchant, M.
    Zeuner, H.
    Gallo, J. D.
    Segal, N. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Multinational study (n=2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391
    Cortes-Funes, H.
    Pritchard, K. I.
    Biganzoli, L.
    Thomssen, C.
    Pierga, J.
    Koza, I.
    Kwong, A.
    Kellokumpu-Lehtinen, P.
    Chlistalla, A.
    Smith, I.
    EJC SUPPLEMENTS, 2009, 7 (02): : 265 - 266
12345